Maelstrom’s Arthur Hayes has been on a selling spree recently, offloading positions in HYPE, ZEC, NEAR and now WLD.
Latest NewsRead More
You might also be interested in reading Talphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financing.